STS Medical Group
Augusto Orsini has extensive work experience in the medical industry, holding various high-level positions. From 2003 to 2005, they served as the Business Manager Acute Care at Molnlycke Health Care. Augusto then joined Amedes S.p.A. in 2005 as the Chief Executive Officer and Member of the Executive Board, a position they held until 2010. In 2009, they also became the President of AEMM BIOTECH S.r.l. In 2010, Orsini joined Servizi Italia Medical as the Chief Executive Officer and Member of the Executive Board, until their departure in 2012. Currently, they are the Chief Executive Officer and Member of the Executive Board at STS Medical Group, a position they have held since 2013.
Augusto Orsini's education history includes the following:
- In 2018, they completed the Executive Health Innovation Management Programme at Imperial College London, focusing on Health/Health Care Administration/Management.
- In 2012, they attended IMD and earned a degree in High Performance Board.
- In 2009, they participated in the International Management Joint Program with Stanford University at the National University of Singapore.
- In 2008, they studied Strategic Innovation at IMD.
- In 2006, they completed a program in Medical Marketing at UCLA Anderson School of Management.
- In 1987-1988, they received a Master's degree in Business Administration and Management, General from Consorzio Studi Postuniversitari Pavese.
- Augusto also has some affiliation with Imperial College London, but the specific details are not provided.
This person is not in any teams
This person is not in any offices
STS Medical Group
STS Medical Group is a fast-growing organization and a leading European player specialized in the manufacturing and distribution of custom procedure trays (CPT) and medical devices designed and customized for surgical theaters. The Group operates in four main lines of business: CPTs; CPT components such as drapes, gowns and gauze; protective clothing; and medical devices for surgical theatres in public and private hospitals, as well as for healthcare facilities, local health services, nursing homes, wholesalers, and pharmacies. Since its foundation STS Medical Group has believed there's one decision that is essential and non-negotiable: transparency. This is a key element to drive sustainability in healthcare. That's why STS is the first in the market to strongly highlight the transparency impact of adopting article 12 compared to article 11 of EU Medical Device Directive 93/42/EEC in the management of CPTs. To reinforce this transparency commitment, STS has developed the Secu family brand that highlight our pledge to never compromise on the quality and security of our products and services STS Medical Group operates through Sengewald, MSP Schmeiser, MSS Medical Set Service, Salvadori and STS Bulgarian Manufacturing Hub, and from Germany, Italy and Bulgaria reaches all the main European markets. Out of the five production plants, three are located in Germany and two in Sandanski, Bulgaria, where STS Medical Group now benefits from one of the largest and most technologically advanced production hubs for medical devices in Europe. Moreover, STS has just opened a new commercial office in Singapore to deliver its transparent and ready-to-use solutions to the fast-developing Asian healthcare market. STS Medical Group is owned by Monitor Clipper Partners, a private equity firm based in Boston (Massachusetts) and Zurich (Switzerland) and Luxembourg, and Augusto Orsini, an executive with over 25 years of experience in the surgical theater solutions market.